Plus, news about BioNTech, Cloudbreak Pharma, DiaMedica Therapeutics, AstraZeneca and Hookipa:
SAB BIO’s $175M: The company, which is developing human anti-thymocyte immunoglobulin for type 1 diabetes, raised the private placement from ...
↧